Clinical Trial

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-25.
Status change: Not Yet Recruiting → Recruiting 2024-07-16
Trial Details
NCT Number NCT06332170
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumor
Enrollment 610 participants
Start Date 2024-04-26
Primary Completion 2026-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-18